Nadia Raban

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

Jacobus Pfisterer, Catherine Shannon, Klaus Baumann et al. · The Lancet Oncology · 2020 · 162 citations

Medicine, Gynecology, Oncology +14

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 128 citations

Medicine, Oncology, Breast Oncology +9

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

Jean‐Emmanuel Kurtz, Éric Pujade-Lauraine, Ana Oaknin et al. · Journal of Clinical Oncology · 2023 · 103 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy

Claude Linassier, Carole Barin, G. Calais et al. · Annals of Oncology · 2000 · 71 citations · Full text

Medicine, Oncology, Radiation Oncology +14

CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial

J. Alexandre, Chris Brown, David Coeffic et al. · British Journal of Cancer · 2012 · 44 citations · Full text

Medicine, Gynecology, Oncology +12